Company / Revenue
Foghorn Therapeutics Inc. Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$22.6M
FY2025
5-year range
$430.0K / $34.2M
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $19M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of +120.9%.
Improved from $19M to $23M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +157.8%
- 5-Year CAGR
- +120.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +120.9%, indicating consistent growth.
- In FY2025, revenue decreased 33.8% year-over-year.
- Peak revenue was recorded in FY2024.
- Lowest revenue in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.6M | -33.8% |
| FY2024 | $34.2M | +77.6% |
| FY2023 | $19.2M | +1357.8% |
| FY2022 | $1.3M | +206.7% |
| FY2021 | $430.0K | +0.0% |
| FY2020 | $430.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026